Research indicates a high development personalized for medical care, especially in Europe. Define the purpose and nature of human biological variation allows the identification of medical care to those most likely to benefit from them. These treatments may include the use of drugs or cell therapies chosen based on patient history, the genetic trait and immunology. Basically, the phenomenon of every single human being creates immense opportunities for personalized medicine.
A new analysis entitled “Personalised Medicine in Europe,” reveals that the market for personalized medicine is currently undergoing a growth with double-digit rates. This trend is particularly significant because it comes from an already high base. The growth rate is bound to improve as European governments promote personalized medical care and thus increase its traditional application.
“The major benefit of personalized medicine is that it improves the design, effectiveness and predictability of a clinical trial, which then help to achieve better results in less time,” says Rasika Ramachandran.
“Personalized medicine helps to reduce the time of subject recruitment in clinical trials, improve the response to medications and minimize adverse reactions.” Personalized medicine also reduces the possibility of misdiagnosis: a diagnosis not only enables faster when applied as a diagnostic test in addition to drug therapy also contributes to the development of a better differentiation of pharmaceutical products.
The effectiveness of the technique theranostics, combined to lower costs associated with research and development represent the main drivers of the market. However, the pharmaceutical and diagnostic companies need to collaborate more closely with the doctors during the process of development of theranostics, so that when the investigation is on the market, support of medical colleagues will help to increase its use. Public and private partnerships, as well as high levels of technological progress to support the discovery and development of biomarkers, will help stimulate the market outlook.
The biggest challenge remains the refund. This issue prevents doctors from prescribing diagnostic tests as in most cases are without funds or are only partially reimbursed. “If the reimbursement issues are resolved or not these tests become affordable enough for a charge to the assisted, diagnostic test companies will face a real crisis,” said Ramachandran. “European governments are striving to resolve the situation, which is a step forward for companies focused on personalized medicine.”
